Fundamental Valuation Report Apellis Pharmaceuticals(APLS:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$44.76 (USD) 04/15/2021 Weighted Valuation$45.71 (USD) Overall RatingFairly valued to slightly Undervalued by 2.1% Valuation Models Comparables: $43.52 …

Apellis Pharmaceuticals (APLS:NAS) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report Ares Management(ARES:NYS) Financial Services:Asset Management This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$55.89 (USD) 04/16/2021 Weighted Valuation$56.44 (USD) Overall RatingFairly valued to slightly Undervalued by 1.0% Valuation …

Ares Management (ARES:NYS) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report AvalonBay Communities(AVB:NYS) Real Estate:REIT – Residential This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$189.81 (USD) 04/16/2021 Weighted Valuation$190.51 (USD) Overall RatingFairly valued to slightly Undervalued by 0.4% …

AvalonBay Communities (AVB:NYS) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report Avery Dennison(AVY:NYS) Industrials:Business Equipment & Supplies This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$198.60 (USD) 04/16/2021 Weighted Valuation$191.54 (USD) Overall RatingFairly valued to slightly Overvalued by 3.6% …

Avery Dennison (AVY:NYS) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report Baker Hughes(BKR:NYS) Energy:Oil & Gas Equipment & Services This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$20.10 (USD) 04/16/2021 Weighted Valuation$19.65 (USD) Overall RatingFairly valued to …

Baker Hughes (BKR:NYS) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report BlackLine(BL:NAS) Technology:Software – Infrastructure This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$119.09 (USD) 04/16/2021 Weighted Valuation$115.54 (USD) Overall RatingFairly valued to slightly Overvalued by 3.0% Valuation Models …

BlackLine (BL:NAS) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report BlackRock(BLK:NYS) Financial Services:Asset Management This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$811.45 (USD) 04/16/2021 Weighted Valuation$776.26 (USD) Overall RatingFairly valued to slightly Overvalued by 4.3% Valuation Models …

BlackRock (BLK:NYS) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report BELLUS Health(BLU:TSE) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$4.57 (USD) / $5.72 (CAD) 04/16/2021 Weighted Valuation$4.58 (USD) / $5.73 (CAD) Use a conversion …

BELLUS Health (BLU:TSE) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report Boralex(BLX:TSE) Utilities:Utilities – Renewable This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$43.56 (CAD) 04/16/2021 Weighted Valuation$44.16 (CAD) Overall RatingFairly valued to slightly Undervalued by 1.4% Valuation Models …

Boralex (BLX:TSE) Fundamental Valuation Report Read more »

Read More

Fundamental Valuation Report Albireo Pharma(ALBO:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$32.92 (USD) 04/15/2021 Weighted Valuation$31.89 (USD) Overall RatingFairly valued to slightly Overvalued by 3.1% Valuation Models Adjusted …

Albireo Pharma (ALBO:NAS) Fundamental Valuation Report Read more »

Read More